UY31406A1 - "producto de dispersion solida que contiene un compuesto a base de n-aril urea". - Google Patents
"producto de dispersion solida que contiene un compuesto a base de n-aril urea".Info
- Publication number
- UY31406A1 UY31406A1 UY31406A UY31406A UY31406A1 UY 31406 A1 UY31406 A1 UY 31406A1 UY 31406 A UY31406 A UY 31406A UY 31406 A UY31406 A UY 31406A UY 31406 A1 UY31406 A1 UY 31406A1
- Authority
- UY
- Uruguay
- Prior art keywords
- solid dispersion
- dispersion product
- aril
- based compound
- product containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Abstract
Un producto de dispersion solida que comprende al menos un agente farmacéuticamente activo a base de N-aril urea o un agente de estructura relacionada que es obtenido mediante a) la preparacion de una mezcla líquida que contiene al menos un agente activo, al menos un agente formador de matriz aceptable para uso farmacéutico, al menos un solvente, y b) la eliminacion del o de los solventes de la mezcla líquida para obtener el producto de dispersion solida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99961307P | 2007-10-19 | 2007-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31406A1 true UY31406A1 (es) | 2009-05-29 |
Family
ID=40089072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY31406A UY31406A1 (es) | 2007-10-19 | 2008-10-17 | "producto de dispersion solida que contiene un compuesto a base de n-aril urea". |
Country Status (23)
Country | Link |
---|---|
US (1) | US20090143423A1 (es) |
EP (1) | EP2197426A2 (es) |
JP (1) | JP2011500647A (es) |
KR (1) | KR20100090689A (es) |
CN (1) | CN101827585A (es) |
AR (1) | AR068916A1 (es) |
AU (1) | AU2008313620A1 (es) |
BR (1) | BRPI0818339A2 (es) |
CA (1) | CA2699335A1 (es) |
CL (1) | CL2008003092A1 (es) |
CO (1) | CO6270303A2 (es) |
CR (1) | CR11441A (es) |
DO (1) | DOP2010000114A (es) |
EC (1) | ECSP10010184A (es) |
GT (1) | GT201000095A (es) |
MX (1) | MX2010004292A (es) |
PE (1) | PE20091041A1 (es) |
RU (1) | RU2010119924A (es) |
TW (1) | TW200922549A (es) |
UA (1) | UA100866C2 (es) |
UY (1) | UY31406A1 (es) |
WO (1) | WO2009050289A2 (es) |
ZA (1) | ZA201002130B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010045402A1 (en) * | 2008-10-17 | 2010-04-22 | Abbott Laboratories | Trpv1 antagonists |
TW201020236A (en) * | 2008-10-17 | 2010-06-01 | Abbott Lab | TRPV1 antagonists |
US20100210682A1 (en) * | 2009-02-19 | 2010-08-19 | Abbott Laboratories | Repeated Dosing of TRPV1 Antagonists |
WO2011032860A1 (de) * | 2009-09-18 | 2011-03-24 | Basf Se | Verfahren zur herstellung von zubereitungen von in wasser schwerlöslichen substanzen |
CN103260609B (zh) * | 2010-12-23 | 2017-08-11 | 雅培股份有限两合公司 | 基于固体分散体的固体延缓制剂 |
US9757355B2 (en) | 2011-01-10 | 2017-09-12 | Celgene Corporation | Oral dosage forms of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide |
EP2907505A3 (en) * | 2011-12-29 | 2015-12-30 | Abbvie Inc. | Solid compositions comprising an HCV inhibitor |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
NZ625087A (en) | 2013-01-31 | 2017-05-26 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
UA116237C2 (uk) | 2013-03-15 | 2018-02-26 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Тверда пероральна дозована композиція інгібітору нсv в аморфному стані |
CA2916183C (en) | 2013-07-03 | 2022-03-29 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with electronic component |
ES2900570T3 (es) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
CA2948221C (en) | 2014-05-20 | 2022-11-22 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
CN106456567A (zh) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 在经皮递送系统中调节活性剂释放的方法 |
CN106456566B (zh) * | 2014-05-20 | 2020-06-16 | Lts勒曼治疗系统股份公司 | 含罗替戈汀的经皮递送系统 |
WO2017112693A1 (en) * | 2015-12-22 | 2017-06-29 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia |
WO2020092100A1 (en) * | 2018-10-30 | 2020-05-07 | Peloton Therapeutics, Inc. | Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof |
MX2022002017A (es) | 2019-08-23 | 2022-03-11 | Mochida Pharm Co Ltd | Metodo para producir derivado de heterociclideno acetamida. |
WO2021039023A1 (ja) | 2019-08-23 | 2021-03-04 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362878A (en) * | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
EP0642498A1 (en) * | 1992-05-28 | 1995-03-15 | Pfizer Inc. | NEW $i(N)-ARYL AND $i(N)-HETEROARYLUREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A:CHOLESTEROL ACYL TRANSFERASE (ACAT) |
EP1015046A2 (en) * | 1998-07-14 | 2000-07-05 | Em Industries, Inc. | Microdisperse drug delivery systems |
US7015233B2 (en) * | 2003-06-12 | 2006-03-21 | Abbott Laboratories | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
US20060089385A1 (en) * | 2004-06-08 | 2006-04-27 | Yong Cui | Pharmaceutical compositions |
EP1796642B1 (en) * | 2004-08-27 | 2008-05-21 | Bayer Pharmaceuticals Corporation | Pharmaceutical compositions in the form of solid dispersions for the treatment of cancer |
WO2006113631A2 (en) * | 2005-04-18 | 2006-10-26 | Rubicon Research Pvt. Ltd. | Bioenhanced compositions |
KR100715355B1 (ko) * | 2005-09-30 | 2007-05-07 | 주식회사유한양행 | 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법 |
EP1959926A1 (en) * | 2005-10-25 | 2008-08-27 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
WO2007066189A2 (en) * | 2005-12-09 | 2007-06-14 | Pfizer Products Inc. | Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea |
US7745448B2 (en) * | 2005-12-28 | 2010-06-29 | Abbott Laboratories Inc. | Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate |
US8030359B2 (en) * | 2006-02-09 | 2011-10-04 | Merck Sharp & Dohme Corp. | Polymer formulations of CETP inhibitors |
-
2008
- 2008-10-17 CL CL2008003092A patent/CL2008003092A1/es unknown
- 2008-10-17 CA CA2699335A patent/CA2699335A1/en not_active Abandoned
- 2008-10-17 PE PE2008001785A patent/PE20091041A1/es not_active Application Discontinuation
- 2008-10-17 RU RU2010119924/15A patent/RU2010119924A/ru not_active Application Discontinuation
- 2008-10-17 UY UY31406A patent/UY31406A1/es not_active Application Discontinuation
- 2008-10-17 JP JP2010529406A patent/JP2011500647A/ja active Pending
- 2008-10-17 KR KR1020107010874A patent/KR20100090689A/ko not_active Application Discontinuation
- 2008-10-17 CN CN200880112161A patent/CN101827585A/zh active Pending
- 2008-10-17 EP EP08840773A patent/EP2197426A2/en not_active Withdrawn
- 2008-10-17 WO PCT/EP2008/064073 patent/WO2009050289A2/en active Application Filing
- 2008-10-17 MX MX2010004292A patent/MX2010004292A/es not_active Application Discontinuation
- 2008-10-17 AR ARP080104542A patent/AR068916A1/es not_active Application Discontinuation
- 2008-10-17 AU AU2008313620A patent/AU2008313620A1/en not_active Abandoned
- 2008-10-17 US US12/253,499 patent/US20090143423A1/en not_active Abandoned
- 2008-10-17 TW TW097140229A patent/TW200922549A/zh unknown
- 2008-10-17 UA UAA201006030A patent/UA100866C2/ru unknown
- 2008-10-17 BR BRPI0818339 patent/BRPI0818339A2/pt not_active IP Right Cessation
-
2010
- 2010-03-25 ZA ZA2010/02130A patent/ZA201002130B/en unknown
- 2010-04-15 GT GT201000095A patent/GT201000095A/es unknown
- 2010-04-16 DO DO2010000114A patent/DOP2010000114A/es unknown
- 2010-04-27 CO CO10049270A patent/CO6270303A2/es not_active Application Discontinuation
- 2010-05-17 EC EC2010010184A patent/ECSP10010184A/es unknown
- 2010-05-19 CR CR11441A patent/CR11441A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR068916A1 (es) | 2009-12-16 |
AU2008313620A1 (en) | 2009-04-23 |
JP2011500647A (ja) | 2011-01-06 |
EP2197426A2 (en) | 2010-06-23 |
WO2009050289A2 (en) | 2009-04-23 |
WO2009050289A3 (en) | 2010-03-25 |
UA100866C2 (ru) | 2013-02-11 |
DOP2010000114A (es) | 2010-05-15 |
BRPI0818339A2 (pt) | 2015-04-22 |
MX2010004292A (es) | 2010-08-02 |
TW200922549A (en) | 2009-06-01 |
CA2699335A1 (en) | 2009-04-23 |
KR20100090689A (ko) | 2010-08-16 |
ECSP10010184A (es) | 2010-06-29 |
US20090143423A1 (en) | 2009-06-04 |
CN101827585A (zh) | 2010-09-08 |
RU2010119924A (ru) | 2011-11-27 |
PE20091041A1 (es) | 2009-08-22 |
ZA201002130B (en) | 2011-11-30 |
GT201000095A (es) | 2012-04-03 |
CO6270303A2 (es) | 2011-04-20 |
CR11441A (es) | 2010-10-25 |
CL2008003092A1 (es) | 2009-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31406A1 (es) | "producto de dispersion solida que contiene un compuesto a base de n-aril urea". | |
DOP2010000117A (es) | Producto de dispersion solida de drogas basadas en n-aril urea | |
CO6321225A2 (es) | Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico | |
CO5580767A2 (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
AR048017A1 (es) | Composicion y metodo para aumentar la biodisponibilidad | |
UY27740A1 (es) | Nuevos compuestos | |
AR055070A1 (es) | Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso | |
DOP2009000124A (es) | Derivados de benzamida como receptores agonista ep4 | |
UY29701A1 (es) | Formulaciones líquidas para la administración controlada de derivados de bencisoxazol | |
AR086115A1 (es) | Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas | |
AR051969A1 (es) | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central | |
AR053517A1 (es) | Proceso para la preparacion de compuestos de tetrazolilo, uso de los mismos en el tratamiento de enfermedades circulatorias y formulaciones farmaceuticas que los contienen. | |
UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
CL2009001766A1 (es) | Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica. | |
UY30736A1 (es) | Compuestos quimicos 537 | |
CY1110037T1 (el) | Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες | |
UY29181A1 (es) | Derivados de bencenosulfonamidas n-sustituidos, composiciones que los contienen, procesos de preparación y aplicaciones | |
CL2008002247A1 (es) | Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros. | |
AR043423A1 (es) | Sistema de liberacion controlada | |
AR039166A1 (es) | Composiciones de venlafaxina base | |
CL2009000980A1 (es) | Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006). | |
CR9407A (es) | Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
CL2007001981A1 (es) | Composicion que comprende al menos un principio activo agroquimico del grupo de los piretroides, al menos un tensioactivo, y al menos un disolvente no miscible en agua; procedimiento para la lucha contra las plagas animales; y su uso. | |
UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
AR026451A1 (es) | Compuestos heterociclicos sililados |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20171017 |